Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia. Hashimoto, M., Saito, Y., Nakagawa, R., Ogahara, I., Takagi, S., Takata, S., Amitani, H., Endo, M., Yuki, H., Ramilowski, J. A, & others Nature Cancer, 2(3):340–356, Nature Publishing Group US New York, 2021.
bibtex   
@article{hashimoto2021combined,
  title={Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia},
  author={Hashimoto, Mari and Saito, Yoriko and Nakagawa, Ryo and Ogahara, Ikuko and Takagi, Shinsuke and Takata, Sadaaki and Amitani, Hanae and Endo, Mikiko and Yuki, Hitomi and Ramilowski, Jordan A and others},
  journal={Nature Cancer},
  volume={2},
  number={3},
  pages={340--356},
  year={2021},
  publisher={Nature Publishing Group US New York}
}

Downloads: 0